ArticleJACC. Case reports2026
Apical Hypertrophic Cardiomyopathy and Elite-Level Sports: A 12-Year Follow-Up Case.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundApical hypertrophic cardiomyopathy (aHCM) is a distinct, rarer phenotype with a potentially more favorable prognosis and lower morbidity than nonapical forms of hypertrophic cardiomyopathy, yet its specific interaction with elite-level sports remains poorly defined. CASE SUMMARY: This case describes an asymptomatic athlete found to have aHCM, for whom engaging in elite sports from ages 17 to 31 years did not lead to adverse morphologic changes or progression of apical fibrosis or disease, even after the cessation of his professional sports career. DISCUSSION: This case underscores the importance of recognizing aHCM as a distinct subtype of hypertrophic cardiomyopathy, potentially exhibiting a more benign interaction with sports. Furthermore, it highlights the value of a multidisciplinary expert panel in providing sports guidance to elite athletes with cardiovascular conditions. TAKE-HOME MESSAGES: Distinguish aHCM as a subtype that may carry a lower risk profile in elite athletes. Multidisciplinary shared decision-making is essential for individualized sports eligibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.